Patent Leaderboard
USPTO Patent Rankings Data through Dec 31, 2025
Home › Therapeutic genome editing in Wiskott-Aldrich syndrome and X-linked thrombocytopenia

Therapeutic genome editing in Wiskott-Aldrich syndrome and X-linked thrombocytopenia

US Patent 11643671 · Granted May 9, 2023

Assignee

Inventors

View full patent text on Google Patents →

More Patents by These Inventors

Vivo gene therapy using intraosseous delivery of a lentiviralgene construct2025
Homology directed repair compositions for the treatment of hemoglobinopathies2025
Homology directed repair compositions for the treatment of hemoglobinopathies2024
Rapamycin resistant cells2024
Engraftable cell-based immunotherapy for long-term delivery of therapeutic prote2024
Engraftable cell-based immunotherapy for long-term delivery of therapeutic prote2024
Method for treating autoimmune disease using CD4 T-cells with engineered stabili2023
Expression of FOXP3 in edited CD34+ cells2023
Expression of FOXP3 in edited CD34+ cells2023
Coupling endonucleases with end-processing enzymes drives high efficiency gene d2020
Enhancing endonuclease based gene editing in primary cells2020
CCR5 disruption of cells expressing anti-HIV chimeric antigen receptor (CAR) der2019